Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.

Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA. · 2016

Read Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. by Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5085160.txt.

Description

Eloah Rabello Suarez and seven co-authors engineer immune cells against kidney cancer in Oncotarget in 2016. Clear cell renal cancer resists cure, and T cells sent against it tire out because tumors raise the PD-L1 brake signal. The team built chimeric antigen receptor T cells aimed at a tumor marker, CAIX. They armed them to release anti-PD-L1 antibodies right at the tumor, cutting the brake locally instead of throughout the body.

In a humanized mouse model, the armed cells beat plain CAR T cells clearly: tumor growth fell fivefold and tumor weight dropped by half to four fifths. Tumors showed less PD-L1 and cell division; the T cells carried more granzyme B, and the antibody also drew natural killer cells in. The authors present self-arming CAR T cells as a rescue for this therapy in solid tumors, where it has disappointed.

Catalog record

CREATORSuarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5085160

Browse the full library · About the Tower of Babel